Sonnet BioTherapeutics Holdings, Inc. (SONN)

SONN Revenue

In the fiscal year ending September 30, 2024, Sonnet BioTherapeutics Holdings had annual revenue of $18.63K, down -87.40%.

• Revenue (ttm): $18.63K
• Revenue Growth: -87.40%
• P/S Ratio: 13.13
• Revenue / Employee: $76,923
• Employees: 13
• Market Cap: 33.11M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Sep 30, 2024	18.63K	-129.18K	-87.40%
Sep 30, 2023	147.81K	-202.14K	-57.76%
Sep 30, 2022	349.94K	-133.68K	-27.64%
Sep 30, 2021	483.63K	-	-
Sep 30, 2020	-	-	-
Dec 31, 2019	30.14M	-	-
Sep 30, 2019	-	-	-
Dec 31, 2018	30.73M	-10.70M	-25.82%
Dec 31, 2017	41.43M	-269.14K	-0.65%
Dec 31, 2016	41.70M	6.35M	17.96%
Dec 31, 2015	35.35M	5.51M	18.46%
Dec 31, 2014	29.84M	21.60M	261.85%
Dec 31, 2013	8.25M	1.40M	20.36%
Dec 31, 2012	6.85M	5.38M	364.05%
Dec 31, 2011	1.48M	1.34M	983.37%
Dec 31, 2010	136.30K	-466.68K	-77.40%
Dec 31, 2009	602.98K	368.92K	157.62%
Dec 31, 2008	234.06K	-297.19K	-55.94%
Dec 31, 2007	531.25K	467.08K	727.91%
Dec 31, 2006	64.17K	-	-
Dec 31, 2005	-	-	-